Avalo Therapeutics (AVTX) Tax Provisions (2017 - 2026)
Avalo Therapeutics' (AVTX) quarterly Tax Provisions came in at $12000.0 in Q1 2026, up 50.0% YoY from $8000.0 in Q1 2025, and down 90.77% on a QoQ basis from $130000.0 in Q4 2025.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Tax Provisions (2017 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 10 years of Tax Provisions data on file, last reported at $12000.0 in Q1 2026.
- Quarterly Tax Provisions rose 50.0% year-over-year to $12000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169000.0 (up 46.96% YoY) and the FY2025 annual result came in at $165000.0, up 44.74% from the prior year.
- Tax Provisions retreated to $12000.0 in Q1 2026, from $130000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $130000.0 in Q4 2025 to a low of -$14000.0 in Q3 2024.
- A 5-year average of $19529.4 and a median of $8000.0 in 2022 frame the typical range for Tax Provisions.
- The widest YoY moves for Tax Provisions: up 1366.67% in 2024, down 275.0% in 2024.
- Tracing AVTX's Tax Provisions over 5 years: stood at $8000.0 in 2022, then tumbled by 212.5% to -$9000.0 in 2023, then soared by 1366.67% to $114000.0 in 2024, then advanced by 14.04% to $130000.0 in 2025, then tumbled by 90.77% to $12000.0 in 2026.
- The last three Tax Provisions figures came in at $12000.0 (Q1 2026), $130000.0 (Q4 2025), and $11000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Avalo Therapeutics | 838.90 Mn | 838.90 Mn | - | 18,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18,000.00 |
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 8,000.00 |